Historical record - last NADAC effective date: 10/11/2017
Product Information
TOPIRAMATE ER 150 MG CAPSULE is a generic product labeled by Upsher-Smith Laboratories LLC, priced at $13.9523 per EA under NDC 00832107515. Its NADAC has been published 34 times since Mar 22, 2017.
FDA first approved this application on Mar 11, 2014. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Upsher-Smith Laboratories LLCNDC
00832107515
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
10/11/2017
Active Ingredients
TOPIRAMATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA205122FDA Approved
3/11/2014
TE Code
AB2
On Market Since
7/7/2014
Pharmacological Classes
Price Statistics
The NADAC for TOPIRAMATE ER 150 MG CAPSULE has been published 34 times since Mar 22, 2017, and over the history we have for it it has risen 9.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.9523 per EA |
|---|---|
| All-time high | $13.9523 (Nov 8, 2017) |
| All-time low | $12.8007 (Mar 22, 2017) |
| Median price | $13.0132 |
| Average price | $13.1709 |
| Largest weekly change | +3.8% (Aug 23, 2017) |
| Weeks tracked | 34 |
| Tracking since | Mar 22, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+9.0%
Last surveyed Nov 8, 2017 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 47% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Upsher-Smith Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOPIRAMATE ER 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TOPIRAMATE ER 150 MG CAPSULE, manufactured by Upsher-Smith Laboratories LLC, is $13.9523 per EA (NDC 00832107515), effective Nov 8, 2017.
How has the price of TOPIRAMATE ER 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TOPIRAMATE ER 150 MG CAPSULE has risen 9.0%. It has been tracked across 34 weekly CMS publications since Mar 22, 2017.
What are the highest and lowest recorded NADAC prices for TOPIRAMATE ER 150 MG CAPSULE?
Since Mar 22, 2017, the NADAC for TOPIRAMATE ER 150 MG CAPSULE has ranged from a low of $12.8007 (Mar 22, 2017) to a high of $13.9523 (Nov 8, 2017), with a median of $13.0132 per EA.
Are there cheaper alternatives to TOPIRAMATE ER 150 MG CAPSULE?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 150 MG SPRINK CAP, is $7.3569 per EA — about 47% below TOPIRAMATE ER 150 MG CAPSULE.
Who manufactures TOPIRAMATE ER 150 MG CAPSULE?
TOPIRAMATE ER 150 MG CAPSULE (NDC 00832107515) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a generic product.